How I treat Ph+ acute lymphoblastic leukemia

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Efficacy and safety of olverembatinib in adult <scp>BCR</scp>::<scp>ABL1</scp>‐positive <scp>ALL</scp> with <scp>T315I</scp> mutation or relapsed/refractory disease2024 · 15 citations
2. 2Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaRCT · 2020 · 247 citations
3. 3Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)Original Research · 2006 · 337 citations
4. 4Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaEarly-Phase Clinical Trial · 2025 · 31 citations
5. 5Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993Prognostic Study · 2009 · 292 citations